Login to Your Account

Epirus touts biosimilar Remicade progress, boosting Zalicus shares

By Michael Fitzhugh
Staff Writer

Thursday, June 12, 2014
Shares of Zalicus Inc., the company that will soon give Epirus Pharmaceuticals Inc. entrée to the public market through a reverse merger, shot up 39.8 percent Thursday as Epirus promoted trial results showing that BOW015, its biosimilar to the anti-tumor necrosis factor therapy Remicade (infliximab, Johnson & Johnson) compared favorably to the branded drug in a phase III equivalence trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription